Article | Open Access | Published:

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

Scientific Reports volume 4, Article number: 4669 (2014) | Download Citation


ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer. A significant association between common single nucleotide polymorphisms (SNPs) in ABCB1 and progression-free survival has been reported in patients with ovarian cancer. Variable paclitaxel clearance due to genotype specific differences in ABCB1 activity in cancer cells and/or normal tissues may underlie the association. Using cell-based models, we evaluated the correlations between ABCB1 expression, polymorphisms, transporter activity and paclitaxel sensitivity in ovarian cancer (n = 10) and lymphoblastoid (n = 19) cell lines. Close associations between ABCB1 expression, transporter function and paclitaxel sensitivity were found in lymphoblastoid cell lines, although we could not demonstrate an association with common SNPs. In ovarian cancer cell lines, ABCB1 expression was low and the association between expression and function was lost. These results suggest that ABCB1 related survival difference in ovarian cancer patients is more likely to be due to differential whole body paclitaxel clearance mediated by normal cells rather than a direct effect on cancer cells.


Ovarian cancer is the seventh leading cause of cancer mortality among women globally. Most patients are treated with paclitaxel and carboplatin chemotherapy after surgery1. However, chemotherapy response varies widely between individuals. While a number of factors including tumor histology, somatic mutations, environmental and drug-drug interactions, can contribute to the inter-individual variability, inherited genetic variations are increasingly understood to influence drug disposition and activity.

Polymorphisms in genes encoding drug transporter proteins are among the most clinically important genotypic variations that may impact on therapeutic agents2. The adenosine triphosphate (ATP)-binding cassette (ABC) transporter, ABCB1, also known as permeability-glycoprotein (P-gp) or multidrug resistance protein 1 (MDR1), is expressed in normal barrier tissues such as the apical membrane of intestine, the canalicular site of hepatocytes, tubular cells of the kidney, lymphocytes, and also various human cancers3. It mediates the rapid exit of a vast spectrum of therapeutic agents from cells including the chemotherapeutic drug paclitaxel4. A number of studies have explored the potential of using ABCB1 polymorphisms as a predictive and/or prognostic marker in ovarian cancer, but no compelling or consistent results have been identified5,6,7. Several factors including patient numbers, study design and analytical methods may cause this discrepancy. In a cohort of 309 patients from the Australian Ovarian Cancer Study (AOCS), we found three common single nucleotide polymorphisms (SNPs) in ABCB1 (C1236T (rs1128503), G2677T/A (rs2032582) and C3435T (rs1045642)) were associated with significant differences in progression-free survival (PFS) for the subgroup of women with ≤ 1 cm residual disease who received paclitaxel and carboplatin first-line chemotherapy. In this subgroup of patients, PFS was significantly longer for individuals who carried the minor T/A alleles at the 2677G>T/A compared with homozygote GG carriers (HZ = 0.61, 95% CI 0.45–0.83; p = 0.002)8. A similar effect was demonstrated in 281 patients from Scottish Randomised Trial in Ovarian Cancer 1 (SCOTROC1) who had no residual disease after surgery and received carboplatin and paclitaxel or docetaxel combination chemotherapy8. On the basis of these findings, we hypothesised that the association between ABCB1 genotype and outcome in ovarian cancer may reflect differential cellular transport of paclitaxel in normal and/or cancer cells.

To investigate this, we used cell-based models to evaluate the associations between ABCB1 genetic polymorphisms, gene expression, transporter activity and paclitaxel sensitivity in both ovarian cancer cell lines and lymphoblastoid cell lines (LCLs) derived from women with ovarian cancer. We reasoned that ovarian cancer cells have multiple and varied genomic and phenotypic alterations that may outweigh any effect of inherited polymorphisms, whereas phenotype-genotype associations may be better appreciated in normal cells such as lymphoblastoid cell lines.


ABCB1 expression was variable but higher in lymphoblastoid cell lines compared with ovarian cancer cells

Relative levels of ABCB1 mRNA expression were determined in 19 LCLs and 10 ovarian cancer cell lines. There was a 20-fold inter-individual variation in ABCB1 expression in LCLs (Figure 1a). ABCB1 expression was also variable in ovarian cancer cells although the level of ABCB1 expression in these cells was very low (Figure 1b).

Figure 1: Relative ABCB1 expression in lymphoblastoid and ovarian cancer cell lines.
Figure 1

ABCB1 mRNA expression was measured by quantitative RT-PCR in (a) 19 lymphoblastoid cell lines and (b) 10 ovarian cancer cell lines. All results were expressed relative to the level expressed in OVCAR-3. The expression in SK-OV-3, A2780 and OVCAR-3 in (a) were measured in parallel to compare the levels of relative expression between lymphoblastoid cell lines and ovarian cancer cell lines. The results presented were the geometric mean of values normalized to the three control genes HPRT, GUSB and PGK1.

LCLs eliminated paclitaxel faster than ovarian cancer cell lines

To examine ABCB1 transporter activity, cellular bodipy-FL-paclitaxel accumulation and efflux were measured in 13 LCLs and six ovarian cancer cell lines selected to cover the spectrum of ABCB1 expression and paclitaxel sensitivity, using flow cytometry. For these experiments, a range of concentrations of bodipy-FL-paclitaxel was tested and 0.1 μM was selected as it allowed rapid accumulation and a steady state level of bodipy-FL-paclitaxel that was able to be measured reproducibly by flow cytometry, but had no obvious effect on cell viability during the short exposure time. Following incubation with 0.1 μM bodipy-FL-paclitaxel, intracellular fluorescence activity reached a steady state in both cell types after 30 minutes (Supplementary Figure 1a). Under these conditions, we found no difference in median intracellular bodipy-FL-paclitaxel fluorescence activity between LCLs and ovarian cancer cells (Figure 2a).

Figure 2: Cellular accumulation and efflux of bodipy-FL-paclitaxel, a fluorescent ABCB1 substrate in lymphoblastoid and ovarian cancer cell lines measured by flow cytometry.
Figure 2

(a) Median bodipy-FL-paclitaxel accumulated in 13 LCLs and six ovarian cancer cell lines, by independent-samples median test; (b) Decreasing bodipy-FL-paclitaxel fluorescence intensity over a 10 minutes efflux time, in one LCL as a representative example; (c) A fitted curve generated by Solve function of Excel as compared to the actual curve of percentage fluorescence retained, in one LCL as a representative example; (d) Median efflux constant KE in LCLs and ovarian cancer cell lines, by independent-samples median test. All results are mean of at least two independent experiments.

Cellular bodipy-FL-paclitaxel fluorescence intensity decreased over the efflux period (Figure 2b) and exhibited a three-phase elimination pattern - an initial rapid efflux phase in the first three to five minutes, followed by a slower efflux phase up to 15 minutes, usually reaching a plateau phase between 15 to 30 minutes (Supplementary Figures 1b & 1c). The presence of an ABC transporter blocker (verapamil) significantly reduced bodipy-FL-paclitaxel efflux rate in all cell lines, both LCLs (n = 13) and ovarian cancer cell lines (n = 6), providing supporting evidence that bodipy-FL-paclitaxel efflux was mediated by the ABCB1 transporter (representative examples shown in Supplementary Figures 1d–1f).

A fitted curve and an efflux constant KE were generated for each cell line based on a three compartment model using the solver function of Microsoft Excel (Figure 2c). The median efflux KE was significantly higher in LCLs compared to ovarian cancer cell lines (0.470 vs 0.124, p = 0.011) in an independent median test, indicating more rapid efflux of paclitaxel from LCLs (Figure 2d). The range of variation in efflux constant KE in LCLs (3.6-fold) and ovarian cancer cell lines (3.2-fold) was similar.

ABCB1 expression was correlated with paclitaxel accumulation and efflux in LCLs

The relationships between ABCB1 mRNA relative expression, bodipy-FL-paclitaxel accumulation and efflux constant KE were assessed in a correlation matrix by Spearman or Pearson correlation tests depending on data distribution. In LCLs, there was an inverse correlation between ABCB1 expression and intracellular bodipy-FL-paclitaxel accumulation (Rs = −0.571, p = 0.041), and a positive correlation between ABCB1 expression and the efflux constant kE (Rs = 0.593, p = 0.033) (Table 1). Paclitaxel accumulation correlated strongly with efflux (R = 0.748, p = 0.003). These results indicated that LCLs expressing higher levels of ABCB1 accumulated less intracellular paclitaxel and eliminated paclitaxel more efficiently.

Table 1: Correlation matrix between ABCB1 relative expression, bodipy-FL-paclitaxel accumulation and efflux constant KE in lymphoblastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test

In contrast, there was no correlation between ABCB1 expression and paclitaxel accumulation or efflux in ovarian cancer cell lines (Table 1).

Ovarian cancer cell lines were more resistant to paclitaxel with a wider variation in IC50

The cytotoxicity of paclitaxel was measured in 19 LCLs and 10 ovarian cancer cell lines (Figure 3). There was a 10-fold variation in paclitaxel IC50 among ovarian cancer cell lines. PEO14 was the most paclitaxel resistant cell line with an IC50 of 15.0 nM, while CAOV-3 the most sensitive with a IC50 of 1.5 nM. LCLs were generally more sensitive to paclitaxel and had a much smaller (2.4-fold) variation in paclitaxel IC50, ranging from 2.9 to 6.8 nM.

Figure 3: Inhibition of proliferation by paclitaxel in lymphoblastoid and ovarian cancer cell lines.
Figure 3

Effect of paclitaxel on cell proliferation was measured in (a) 19 lymphoblastoid cell lines and (b) 10 ovarian cancer cell lines using the CellTitre AQueous One Solution Cell Proliferation Assay, measured after 72 hrs drug exposure, represented as a percentage of vehicle treated control. Results are mean with standard error of mean of three independent experiments performed in triplicate.

Paclitaxel toxicity correlated with efflux in lymphoblastoid cell lines

In simple linear regression analysis, there was a trend of correlation between ABCB1 expression and paclitaxel IC50 (r = 0.429, p = 0.067) (Figure 4a) and a trend of inverse correlation between paclitaxel accumulation and toxicity (r = −0.546, p = 0.053) (Figure 4c) in LCLs. The correlation between paclitaxel efflux constant kE and paclitaxel IC50 was strongly positive (r = 0.819, p = 0.001) (Figure 4e), demonstrating that LCLs that eliminated paclitaxel more efficiently were more resistant to paclitaxel. In multiple linear regression analysis, paclitaxel efflux constant KE was the only independent variable strongly correlating with paclitaxel IC50 (Beta coefficient = 0.945, p = 0.009) (Table 2).

Figure 4: Relationship between growth inhibitory effects of paclitaxel, ABCB1 expression and cellular drug accumulation and efflux.
Figure 4

Paclitaxel growth inhibitory effect (IC50) was determined in 13 lymphoblastoid cell lines (a), (c) and (e) and 6 ovarian cancer cell lines (b), (d) and (f) by CellTitre AQueous One Solution Cell Proliferation Assay after 72 hrs drug exposure. ABCB1 mRNA expression (a) and (b) was measured by RT-PCR and bodipy-FL-paclitaxel accumulation (c) and (d) and efflux (e) and (f) were measured by flow cytometry. The correlation between paclitaxel IC50 and ABCB1 expression (a) and (b), paclitaxel IC50 and drug accumulation (c) and (d) and the correlation between IC50 and drug efflux constant KE (e) and (f) were determined by simple linear regression analysis.

Table 2: Multiple linear regression analysis of ABCB1 expression, bodipy-FL-paclitaxel accumulation, efflux and paclitaxel IC50

There were no associations between paclitaxel cytotoxicity and accumulation or efflux in ovarian cancer cell lines (Figures 4b, 4d and 4f and Table 2). Exploratory analyses were performed in three ovarian cancer cell lines with relatively high ABCB1 expression (ES-2, MDAH2774 and CAOV-3). Although there was trend of correlation between ABCB1 expression and paclitaxel IC50, it was not statistically significant (p = 0.206). There was no association between efflux, accumulation and paclitaxel IC50, but the very small sample number (n = 3) limited the interpretation of these results.

No associations between ABCB1 genotype and paclitaxel cytotoxicity or ABCB1 expression and transporter activity were identified

Common ABCB1 SNPs were examined in all cell lines. No associations were observed between SNPs in ABCB1 exon 12 (C1236T), 21 (G2677T/A) and 26 (C3435T) and ABCB1 expression (Supplementary Figure 2), paclitaxel accumulation, efflux or cytotoxicity in LCLs or ovarian cancer cell lines (Jonckheere-Terpstra test for ordered alternatives) (Figure 5).

Figure 5: Association between growth inhibitory effects of paclitaxel and ABCB1 genotypes.
Figure 5

Paclitaxel growth inhibitory effects (IC50) were determined in 19 lymphoblastoid cell lines (a), (c) and (e) and 10 ovarian cancer cell lines (b), (d) and (f), by CellTitre AQueous One Solution Cell Proliferation Assay after 72 hrs drug exposure. ABCB1 genotype was determined by iPLEX genotyping on Sequenom's MassARRAY platform. Associations between IC50 and ABCB1 genotypes at C1236T (a) and (b), G2677T/A (c) and (d) and C3435T (e) and (f) were analysed by Jonckheere-Terpstra test.


Several studies have suggested an association between ABCB1 genotypes and clinical outcome in cancer patients9,10,11, including ovarian cancer5,8,11,12. To investigate whether this association reflected differences in ABCB1 mediated transport of paclitaxel in normal or ovarian cancer cells, we compared ABCB1 expression, paclitaxel efflux, cytotoxicity and polymorphisms in normal and ovarian cancer cell lines under the same experimental conditions. In LCLs there was a clear association between ABCB1 expression levels, the rate of paclitaxel efflux and cytotoxicity. ABCB1 is responsible for the apical transport of various chemotherapeutic agents like paclitaxel. The degree of expression and the functionality of the transporter can directly affect the intracellular concentration of paclitaxel, therefore its growth inhibitor effects. As a result, more efficient efflux and higher relative ABCB1 expression can lead to higher paclitaxel IC50. In contrast, ABCB1 expression in ovarian cancer cells was very low and not associated with paclitaxel efflux or cytotoxicity.

ABCB1 transporters are expressed and functionally active in all peripheral blood cells, except in granulocytes13. The efficient efflux of chemotherapeutic agents in peripheral blood and haematopoietic cells may confer a degree of protection to these cell types. This finding is consistent with the observations of pioneers such as Skipper and Schabel, who found that some cancer cells recovered more slowly (or not at all) compared to the more robust non-cancer cells when incubated together in a high concentration of cytotoxic drugs for hours or days, followed by longer periods of recovery14.

We found no apparent association between ABCB1 SNPs and expression, efflux or cytotoxicity in LCLs. This is in contrast with the study of 31 healthy Caucasian volunteers by Hitzl et al., which reported a significant correlation between ABCB1 genotypes at position 3435 with the efflux of rhodamine, an ABCB1 substrate, from freshly isolated CD56+ natural killer cells15. They also demonstrated a correlation between genotype and mRNA expression in leukocytes. Specifically these investigators reported that subjects who were homozygous CC at position 3435 had faster rhodamine efflux from CD56+ natural killer cells and higher ABCB1 mRNA expression in leukocytes than subjects with the TT genotype. More recently Wong et al. reported that ABCB1 genotype was associated with hepatic elimination of ABCB1 substrate technetium Tc99m-labeled sestamibi in a cohort of cancer patients16. In their study, patients with CC genotype at position 3435 of ABCB1 gene had faster hepatic sestamibi clearance than TT genotype. These data indicated potential genotype related differences in ABCB1 function, which are consistent with our clinical findings in ovarian cancer patients showing women with CC genotype at position 3435 had worse PFS8.

Limitations of this study to detect an association between ABCB1 genotype and paclitaxel effect in normal cells include low levels of absolute ABCB1 expression in LCLs, compared to liver and bowel; the relatively small number of LCLs examined (n = 19), and the potential impact of exogenous factors during the process of EBV-transformation and in vitro growth that may modify the phenotypes compared with in vivo analyses.

ABCB1 is over-expressed in tumors that originate from tissues expressing physiologically high levels of ABCB1 such as adrenal gland, kidney, liver and colon17. In cell lines derived from these tumors, an inverse correlation between ABCB1 expression and sensitivities to chemotherapeutic drugs that are substrates of ABCB1 transport has been observed18,19,20. Consistent with the reported low level expression in normal ovaries and untreated epithelial ovarian cancer3,21, we found ABCB1 was expressed at very low levels in the panel of 10 ovarian cancer cell lines. The presence of verapamil, an ABCB1 blocker, inhibited paclitaxel efflux in all ovarian cancer cell lines tested regardless of the level of ABCB1 expression, suggesting ABCB1 transporter is functional in all ovarian cancer cell lines. Despite the lower levels of ABCB1 expression and less efficient paclitaxel elimination, some ovarian cancer cell lines were more resistant to paclitaxel than LCLs. Ovarian cancer cells have multiple genomic alterations and the loss of association between ABCB1 expression, paclitaxel elimination and paclitaxel resistance could be due to a variety of factors including somatic mutations22, oncogene expression and amplification or inappropriate growth factor regulation23 in ovarian cancer cells. Other factors that could potentially contribute to paclitaxel resistance despite low ABCB1 expression in ovarian cancer cells, include alterations in tubulin binding and dynamics due to tubulin mutation24, altered expression of microtubule-associated proteins (MAP)25 and decreased sensitivity to apoptosis-induced stimuli.

Genomic differences between cancer cell lines and tissue samples have been pointed out in several studies22,26,27. So primary ovarian cancer cells, freshly isolated from either solid tumor or malignant ascites, may offer an experimental system that resembles the patient's situation more closely. The ovarian cancer cell lines used in this study were derived from tumors of various histological subtypes and carry a variety of mutations22. Restricting analyses to cell lines with a similar histological/genomic profile may yield a different result.

Although our study did not confirm the presence of an ABCB1 genotype-phenotype correlation in LCLs or ovarian cancer cell lines, the strong association we found between ABCB1 expression, transporter function and paclitaxel cytotoxicity in LCLs, together with the very low level ABCB1 expression in the panel of 10 ovarian cancer cell lines, suggests that the observed ABCB1 genotype-related outcome differences in ovarian cancer patients is more likely to be due to differential, whole body elimination of paclitaxel rather than a direct effect on cancer tissues. Few studies published to date have assessed the effects of ABCB1 genotypes on paclitaxel clearance in ovarian cancer patients7,28,29, and the results have been contradictory. Possible reasons include small patient numbers and significant variation in paclitaxel dosage and infusion time. Our results suggest that further detailed assessment of the effect of SNPs in ABCB1, and potentially SNPs in other genes on paclitaxel clearance and ultimate association with ovarian cancer survival is warranted.


Cell line authentication and culture conditions

EBV-transformed B-lymphoblastoid cell lines (LCLs) from 19 Caucasian ovarian cancer patients were obtained through the Australian Ovarian Cancer Study (AOCS)30. Human ovarian cancer cell lines A2780, COLO316, JAM, PEO1, PEO14, OVCAR-3 (Professor Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Australia), CAOV-3, ES-2 and SK-OV-3 (ATCC, Manassas, VA, USA) were authenticated by STR profiling (Promega Cell ID System, Promega Corporation, Madison WI, USA) against published profiles. MDAH2774 was profiled, but no reference was available for comparison.

LCLs and ovarian cancer cells were maintained in RPMI 1640 (Invitrogen Corporation, Carlsbad CA, USA) supplemented with 15% and 10% fetal calf serum (SAFC Biosciences, Lenexa KS, USA) v/v respectively. All cells were grown at 37°C in a humidified atmosphere containing 5% CO2. Cells were tested regularly for Mycoplasma contamination and shown to be negative.

This study was approved by the Western Sydney Local Health District and Queensland Institute of Medical Research Human Research Ethics Committees, and AOCS was approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland Institute of Medical Research, University of Melbourne and all participating hospitals. Methods were carried out in accordance with the approved guidelines and informed consent was obtained from all subjects.

ABCB1 genotyping

Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Common ABCB1 SNPs at exon 12 (C1236T), 21 (G2677T/A) and 26 (C3435T) were examined by iPLEX genotyping on Sequenom's MassARRAY platform8.

Expression of ABCB1 mRNA by real-time PCR

RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). RNA was reverse transcribed with MMLV reverse transcriptase (Life Technologies, Carlsbad CA, USA) as previously described31. Real-time PCR quantitation of gene expression utilising TaqMan gene expression assays (ABCB1, assay ID Hs00184500 m1; GUSB, assay ID 4326320E; HPRT, assay ID 4326321E; PGK1, assay ID 4326318E) were conducted using a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City CA, USA). Gene expression levels were determined using the ΔΔCt method and expressed relative to a calibrator. Expression values were calculated as the geometric mean of values normalized to the three control genes HPRT, GUSB and PGK1.

Paclitaxel growth inhibition assay

Drug concentrations that inhibited 50% of cell growth (IC50) were determined using the CellTitre AQueous One Solution Cell Proliferation Assay (Promega, Madison WI, USA). Briefly, cell suspensions (100 μL, 5000 cells for LCLs and 10000 cells for cancer cell lines) were plated in 96-well flat bottom plates. After 24-h incubation, cells were treated with 50 μl of increasing concentrations (0–15 nM) of paclitaxel injection solution (Sigma-Aldrich Inc, St Louis MA, USA) and vehicle control (Cremophor EL™ and dehydrated ethanol USP (1:1, v/v)) for 72 hours before adding 30 μL of MTS reagent. Following 3-h incubation, absorbance at 490 nm was recorded on a Wallac Victor2 1420 Multilabel Counter (Perkin Elmer Life Sciences, Waltham, MA, USA). Percent survival was quantified according to the manufacturer's protocol. Paclitaxel IC50 was determined by curve fitting of percentage cell survival against concentrations of paclitaxel. All experiments were conducted at least three experiments in triplicate.

Bodipy-FL-paclitaxel accumulation and efflux assay

To allow bodipy-FL-paclitaxel (Invitrogen, Carlsbad CA, USA) accumulation, cell suspensions at densities of 106 cells per mL were incubated with bodipy-FL-paclitaxel at a concentration of 0.1 μM for 30 minutes at 37°C and 5% CO2. After accumulation, cells were aliquoted into Eppendorf tubes (Eppendorf, Hamburg, Germany) (1 mL per tube) on ice, centrifuged for 5 minutes at 400 g at 4°C and washed twice with ice old PBS to remove extracellular bodipy-FL-paclitaxel.

After washing, the positive control sample was resuspended in 1 mL ice-cold medium for the measurement of the baseline fluorescence using a FACSCanto flow cytometer (488 nm, 20 mW laser; 530/30 band pass filter) (BD Biosciences, Franklin Lakes, New Jersey, USA). The remaining samples were resuspended in 1 mL 37°C medium and incubated at 37°C for 0.5, 1, 3, 5, 10, 15 and 30 minutes respectively to allow paclitaxel efflux. Three samples were incubated in medium containing verapamil (Abbott Australasia, Botany, Australia) at a concentration of 1 μg/mL for 5, 10 and 15 minutes respectively.

Appropriate threshold values were set to exclude clumps and debris, and samples were gated on forward scatter vs side scatter to include lymphoblastoid or cancer cell populations. A minimum of 10,000 events were collected per sample. Data was expressed as median bodipy-FL-paclitaxel fluorescence. Bodipy-FL-paclitaxel fluorescence in control sample, after baseline dye uptake, was set as 100%. Bodipy-FL-paclitaxel fluorescence in efflux samples, exposed to different efflux time periods, was used to calculate the percentage of bodipy-FL-paclitaxel retained in the cells in comparison with control.

Pharmacokinetic modelling of bodipy-FL-paclitaxel cellular elimination

Intracellular paclitaxel fluorescence intensity is the combined result of active efflux through ABCB1 transporter, passive diffusion/efflux through the cell membrane and redistribution of the fluorescence from medium into the cells at the late phase of efflux assay. Hence a three compartment model was developed to reflect the changes. The summation of the kinetics of intra-cellular fluorescence resulted in an exponential equation of the following form: percentage of intra-cellular fluorescence at time t = Ae−kEt + Be−kDt + Ce−kRt, where A, B and C are constants; kE is the active efflux constant; kD is the passive diffusion/efflux constant and kR is the redistribution constant. This equation was derived from fluorescence data of cell lines by the use of the solver function of Microsoft Excel (Office XP; Microsoft Corp, Redmond, Wash, USA). The efflux constant (kE) was used as the measure of bodipy-FL-paclitaxel cellular efflux rate and ABCB1 transporter activity.

Statistical analysis

Spearman or Pearson correlation tests were used to assess the relationships between ABCB1 expression, bodipy-FL-paclitaxel accumulation and efflux constant KE. Linear regression analysis was performed to assess their impacts on paclitaxel IC50. Independent median test was used to compare the median bodipy-FL-paclitaxel accumulation and efflux between LCLs and ovarian cancer cell lines. Nonparametric Jonckheere-Terpstra test was used to compare the distribution of ABCB1 expression, paclitaxel cytotoxicity and bodipy-FL-paclitaxel efflux constant kE between cell lines of different genotypes. All calculations were performed with SPSS for Windows v21 (SPSS, Chicago, Ill, USA). All tests are two-tailed and p-values ≤ 0.05 were considered to be of statistical significance.


  1. 1.

    Cancer of the ovary. The N Engl J Med 351, 2519–2529 (2004).

  2. 2.

    Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Bio 448, 63–76 (2008).

  3. 3.

    et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81, 116–124 (1989).

  4. 4.

    Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112, 457–473 (2006).

  5. 5.

    , , , & mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12, 854–859 (2006).

  6. 6.

    et al. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 124, 575–581 (2012).

  7. 7.

    et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 11, 113–120 (2011).

  8. 8.

    et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14, 5594–5601 (2008).

  9. 9.

    et al. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis 24, 895–905 (2009).

  10. 10.

    et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120, 4197–4204 (2012).

  11. 11.

    et al. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 139, 421–428 (2013).

  12. 12.

    , , , & Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26, 2227–2232 (2006).

  13. 13.

    et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80, 2729–2734 (1992).

  14. 14.

    , & Experimental Evaluation of Potential Anticancer Agents. Xiii. On the Criteria and Kinetics Associated with “Curability” of Experimental Leukemia. Cancer Chemother Rep 35, 1–111 (1964).

  15. 15.

    et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11, 293–298 (2001).

  16. 16.

    et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 77, 33–42 (2005).

  17. 17.

    et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84, 265–269 (1987).

  18. 18.

    et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 86, 700–705 (1994).

  19. 19.

    , & Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines. Urol Res 18, 309–312 (1990).

  20. 20.

    , , & Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer 41, 1811–1818 (2005).

  21. 21.

    et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol 131, 8–14 (2013).

  22. 22.

    , , , & Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4, 2126 (2013).

  23. 23.

    et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

  24. 24.

    , , & Mechanisms of Taxol resistance related to microtubules. Oncogene 22, 7280–7295 (2003).

  25. 25.

    et al. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 68, 553–557 (2011).

  26. 26.

    , , , & Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 5, 55 (2006).

  27. 27.

    , , & A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Research 64, 2805–2816 (2004).

  28. 28.

    et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104, 130–137 (2009).

  29. 29.

    et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer 16, 979–985 (2006).

  30. 30.

    et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14, 5198–5208 (2008).

  31. 31.

    et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24, 1546–1553 (2006).

Download references


This project was supported by the National Health and Medical Research Council (NHMRC) of Australia (scholarship to B.G.), Cancer Institute New South Wales and Cancer Australia (552481). AdeF is funded by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre. We gratefully acknowledge the cooperation of the institutions that supported the study. We also acknowledge the contribution of Australian Ovarian Cancer Study Group (full list can be found at, all study nurses and research assistants and would like to thank all of the women who participated in AOCS. AOCS was supported by U.S. Army Medical Research and Materiel Command DAMD17-01-1-0729, NHMRC Enabling Grant 400413 and Project Grant 400281, the Cancer Council Tasmania and the Cancer Foundation of Western Australia.

Author information

Author notes

    • Rosemary L. Balleine
    •  & Anna deFazio

    These authors contributed equally to this work.


  1. Department of Gynaecological Oncology, Westmead Hospital

    • Bo Gao
    • , Catherine Emmanuel
    •  & Anna deFazio
  2. Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, Australia

    • Bo Gao
    • , Catherine Emmanuel
    • , Paul Harnett
    • , Rosemary L. Balleine
    •  & Anna deFazio
  3. Children's Cancer Institute Australia, Sydney, Australia

    • Amanda Russell
    • , Michelle Henderson
    • , Michelle Haber
    •  & Murray Norris
  4. QIMR Berghofer Medical Research Institute, Brisbane, Australia

    • Jonathan Beesley
    • , Xiao Qing Chen
    • , Sue Healey
    • , Sharon E. Johnatty
    •  & Georgia Chenevix-Trench
  5. Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia

    • Mark Wong
    • , Paul Harnett
    • , Rosemary L. Balleine
    •  & Anna deFazio
  6. Peter MacCallum Cancer Centre, East Melbourne, Australia

    • Laura Galletta
    •  & David Bowtell
  7. Sir Peter MacCallum Department of Oncology

    • David Bowtell
  8. Department of Pathology, University of Melbourne, Melbourne, Australia

    • David Bowtell
  9. Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Australia

    • David Bowtell
  10. Pathology West ICPMR Westmead, Sydney, Australia

    • Rosemary L. Balleine
  11. Peter MacCallum Cancer Centre, Melbourne, Australia

    • Nadia Traficante
    • , Sian Fereday
    • , Kelly Phillips
    • , Danny Rischin
    • , Stephen Fox
    • , Daryl Johnson
    • , Paul Waring
    • , Stephen Lade
    • , Maurice Loughrey
    • , Neil O’Callaghan
    • , William Murray
    • , Izak Haviv
    • , Leanne Bowes
    • , Debra Giles
    • , Joy Hendley
    •  & Katherine Alsop
  12. Sir Peter MacCallum Department of Oncology, Department of Pathology and Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Australia

    • David Bowtell
  13. QIMR Berghofer Medical Research Institute, Brisbane, Australia

    • Adle Green
    • , Penelope Webb
    • , Sue Moore
    • , Karen Harrap
    • , Troy Sadkowsky
    • , Nirmala Pandeya
    • , David Purdie
    • , David Whiteman
    • , Mary-Rose Malt
    • , Barbara Alexander
    • , Pat Ashover
    • , Sue Brown
    • , Tracy Corrish
    • , Lyn Green
    • , Leah Jackman
    • , Kaltin Ferguson
    • , Karen Martin
    • , Adam Martyn
    •  & Barbara Ranieri
  14. Westmead Institute for Cancer Research, University of Sydney at WestmeadMillennium Institute, Sydney, Australia

    • Jillian Hung
    •  & Yoke-Eng Chiew
  15. Victorian Cervical Cytology Registry, Melbourne, Australia

    • Dorota Gertig
  16. Canberra Hospital, Canberra, ACT, Australia

    • Robin Stuart-Harris
  17. Bankstown Hospital, Sydney, NSW, Australia

    • Fred Kirsten
  18. Hornsby Hospital, Sydney, NSW, Australia

    • Josie Rutovitz
  19. Illawarra Area Health Services, Wollongong, NSW, Australia

    • Peter Clingan
    •  & Amanda Glasgow
  20. John Hunter Hospital, Newcastle, NSW, Australia

    • Anthony Proietto
    • , Stephen Braye
    • , Greg Otton
    • , Anne Mellon
    •  & Randall Robertson
  21. Nepean Hospital, Sydney, NSW, Australia

    • Jennifer Shannon
  22. Newcastle Mater Misericordiae Hospital, Newcastle, NSW, Australia

    • Tony Bonaventura
    •  & James Stewart
  23. Port Macquarie Base Hospital, Port Macquarie, NSW, Australia

    • Stephen Begbie
  24. Prince of Wales Hospital, Sydney, NSW, Australia

    • Michael Friedlander
  25. Royal North Shore Hospital, Sydney, NSW, Australia

    • David Bell
    • , Sally Baron-Hay
    • , Alan Ferrier (dec.)
    • , Greg Gard
    • , David Nevell
    • , Nick Pavlakis
    • , Sue Valmadre
    • , Barbara Young
    •  & Jane Maidens
  26. Royal Hospital for Women, Sydney, NSW, Australia

    • Catherine Camaris
    • , Roger Crouch
    • , Lyndal Edwards
    • , Neville Hacker
    • , Donald Marsden
    • , Greg Robertson
    • , Trish Vanden Bergh
    • , Marian Jones
    •  & Patricia Mackenzie
  27. Royal Prince Alfred Hospital, Sydney, NSW, Australia

    • Phillip Beale
    • , Jane Beith
    • , Jonothan Carter
    • , Chris Dalrymple
    • , Anne Hamilton
    • , Roger Houghton
    • , Peter Russell
    •  & Kath Nattress
  28. St George Hospital, Sydney, NSW, Australia

    • Matthew Links
  29. St Vincent’s Hospital, Sydney, NSW, Australia

    • John Grygiel
  30. Wagga Wagga Base Hospital, Wagga Wagga, NSW, Australia

    • Jane Hill
  31. Westmead Hospital, Sydney, NSW, Australia

    • Alison Brand
    • , Karen Byth
    • , Richard Jaworski
    • , Raghwa Sharma
    • , Anita Achen
    • , Gerard Wain
    • , Yoke-Eng Chiew
    • , Annie Stenlake
    •  & Helen Sullivan
  32. Mater Misericordiae Hospitals, Brisbane, Queensland, Australia

    • Bruce Ward
    •  & David Papadimos
  33. Royal Women’s Hospital, Brisbane, Queensland, Australia

    • Alex Crandon
    • , Margaret Cummings
    • , Ken Horwood
    • , Andreas Obermair
    • , Lew Perrin
    • , David Wyld
    •  & Jim Nicklin
  34. Wesley Hospital, Brisbane, Queensland, Australia

    • Jim Nicklin
  35. Royal Adelaide Hospital and Burnside Memorial Hospital, Adelaide, SA, Australia

    • Margaret Davy
    • , Martin K Oehler
    • , Chris Hall
    • , Tom Dodd
    • , Tabitha Healy
    • , Ken Pittman
    •  & Jo White
  36. Flinders Medical Centre, Adelaide, SA, Australia

    • Doug Henderson
    •  & Jo White
  37. Queen Elizabeth HospitalAdelaide, SA, Australia

    • John Miller
    • , John Pierdes
    •  & Jo White
  38. Royal Hobart Hospital, Hobart, Tasmania, Australia

    • Penny Blomfield
    • , David Challis
    • , Robert McIntosh
    • , Andrew Parker
    •  & Victoria Jayde
  39. Freemasons Hospital, Melbourne, Victoria, Australia

    • Bob Brown
    •  & Robert Rome
  40. Mercy Hospital for Women, Melbourne, Victoria, Australia

    • David Allen
    • , Peter Grant
    • , Simon Hyde
    • , Rohan Laurie
    •  & Melissa Robbie
  41. Monash Medical Centre, Melbourne, Victoria, Australia

    • David Healy
    • , Tom Jobling
    • , Tom Manolitsas
    • , Jane McNealage
    • , Peter Rogers
    • , Beatrice Susil
    • , Eric Sumithran
    • , Ian Simpson
    •  & Pamela Mamers
  42. Royal Women’s Hospital, Melbourne, Victoria, Australia

    • Virginia Billson
    • , Jan Pyman
    • , Debra Neesham
    •  & Michael Quinn
  43. Border Medical Oncology, Wodonga, Victoria, Australia

    • Craig Underhill
  44. Andrew Love Cancer Centre, Geelong, Victoria, Australia

    • Richard Bell
  45. Ballarat Base Hospital, Ballarat, Victoria, Australia

    • Leong-Fook Ng
  46. Bendigo Health Care Group, Bendigo, Victoria, Australia

    • Robert Blum
  47. Peninsula HealthFrankston, Victoria, Australia

    • Vinod Ganju
  48. School for Women’s and Infants’ Health, University of Western Australia and the Western Australian Gynaecologic Cancer Service, Perth, WA, Australia

    • Ian Hammond
    •  & Yee Leung
  49. King Edward Memorial Hospital, Perth, WA, Australia

    • Anthony McCartney (dec.)
  50. Mount Hospital, Perth, WA, Australia

    • Martin Buck
  51. WARTN,Western Australia Research Tissue Network, Perth, WA, Australia

    • Nikolajs Zeps
    • , Trudy Schmidt
    • , Helen Shirley
    • , Colleen Ball
    • , Cherry Young
    • , Suzanna Viduka
    • , Hoa Tran
    • , Sanela Bilic
    •  & Lydia Glavinas
  52. St John of God Hospital, Perth, WA, Australia

    • Nikolajs Zeps
    •  & Julia Brooks


  1. Australian Ovarian Cancer Study Group


  1. Search for Bo Gao in:

  2. Search for Amanda Russell in:

  3. Search for Jonathan Beesley in:

  4. Search for Xiao Qing Chen in:

  5. Search for Sue Healey in:

  6. Search for Michelle Henderson in:

  7. Search for Mark Wong in:

  8. Search for Catherine Emmanuel in:

  9. Search for Laura Galletta in:

  10. Search for Sharon E. Johnatty in:

  11. Search for David Bowtell in:

  12. Search for Michelle Haber in:

  13. Search for Murray Norris in:

  14. Search for Paul Harnett in:

  15. Search for Georgia Chenevix-Trench in:

  16. Search for Rosemary L. Balleine in:

  17. Search for Anna deFazio in:


B.G., R.B. and A.deF. wrote the main manuscript and were responsible for project design and conduct; B.G. conducted most of the experiments and prepared Figures 1–5, and Supplementary Figures 1 and 2; A.R., M.He., M.Ha. and M.N. contributed to data for Figures 1, 3, 5 and Supplementary Figure 2. J.B., X.Q.C., S.H., S.J. and G.C.-T. contributed to data for Figure 5 and Supplementary Figure 2; the Australian Ovarian Cancer Study, L.G. and D.B. provided study materials used in Figures 1–5, and Supplementary Figures 1 and 2; M.W., C.E. and P.H. contributed to data analysis and interpretation. All authors reviewed the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Anna deFazio.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary figures

About this article

Publication history





Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.